LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

Home・Akcijų sąrašas・Innoviva Inc

Innoviva Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

22.8 -1.21

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

22.69

Max

23.13

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-55M 187M
Pardavimai	-20M 98M
P/E Sektoriaus vid.	3.597 51.415
Pelnas, tenkantis vienai akcijai	0.468
Pelno marža	190.415
Darbuotojai	159
EBITDA	-160M 48M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+49.52% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-04

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-40M 1.7B
Ankstesnė atidarymo kaina	24.01
Ankstesnė uždarymo kaina	22.8

Naujienos nuotaikos

By Acuity

50%

171 / 346 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

18.57 / 18.75 Palaikymas ir pasipriešinimas

Innoviva Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-14 22:44; UTC

Įsigijimai, susijungimai, perėmimai

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

2026-05-14 22:27; UTC

Įsigijimai, susijungimai, perėmimai

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

2026-05-14 22:12; UTC

Uždarbis

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

2026-05-14 21:52; UTC

Įsigijimai, susijungimai, perėmimai

LVMH to Sell Marc Jacobs

2026-05-15 00:00; UTC

Uždarbis

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

2026-05-14 23:57; UTC

Įsigijimai, susijungimai, perėmimai

Kakao: Stake Sales Aim to Secure Funds for Future Investments

2026-05-14 23:56; UTC

Įsigijimai, susijungimai, perėmimai

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

2026-05-14 23:56; UTC

Įsigijimai, susijungimai, perėmimai

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

2026-05-14 23:56; UTC

Rinkos pokalbiai

Gold Prices Rise on Strong Demand -- Market Talk

2026-05-14 23:56; UTC

Įsigijimai, susijungimai, perėmimai

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

2026-05-14 23:50; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-14 23:50; UTC

Rinkos pokalbiai

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

2026-05-14 23:47; UTC

Uždarbis

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

2026-05-14 23:47; UTC

Uždarbis

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

2026-05-14 23:46; UTC

Uždarbis

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

2026-05-14 23:46; UTC

Uždarbis

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

2026-05-14 23:28; UTC

Rinkos pokalbiai

New Zealand's Economy Faltering Amid Shocks -- Market Talk

2026-05-14 23:00; UTC

Rinkos pokalbiai

Australia's One Nation Party Leads In The Polls -- Market Talk

2026-05-14 22:46; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-14 22:46; UTC

Rinkos pokalbiai

Court Decision 'Negative But Balanced' for Coles -- Market Talk

2026-05-14 22:46; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-14 22:35; UTC

Rinkos pokalbiai

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

2026-05-14 22:11; UTC

Įsigijimai, susijungimai, perėmimai

LVMH Agrees to Sell Marc Jacobs -- WSJ

2026-05-14 22:06; UTC

Rinkos pokalbiai

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

2026-05-14 22:04; UTC

Uždarbis

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

2026-05-14 22:04; UTC

Uždarbis

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

2026-05-14 22:04; UTC

Uždarbis

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

2026-05-14 22:00; UTC

Uždarbis

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

2026-05-14 21:55; UTC

Uždarbis

Nu Holdings 1Q EPS 18c >NU

2026-05-14 21:55; UTC

Uždarbis

Nu Holdings 1Q Rev $4.97B >NU

Akcijų palyginimas

Kainos pokytis

Innoviva Inc Prognozė

Kainos tikslas

By TipRanks

49.52% į viršų

12 mėnesių prognozė

Vidutinis 34.6 USD 49.52%

Aukščiausias 46 USD

Žemiausias 18 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Innoviva Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Innoviva Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

18.57 / 18.75Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Rinkos nuotaikos

By Acuity

171 / 346 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.